Corbus Pharmaceuticals to Host In-Person and Virtual KOL Event at ASCO 2026
NORWOOD, Mass., May 05, 2026 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP), a clinical-stage company focused on promising new therapies in oncology and obesity, today announced that it will host an in-person and virtual KOL event at the 2026 American Society of Clinical Oncology (ASCO) annual meeting to discuss updated data from the Phase 1/2 clinical study of CRB-701 in 75 participants with head and neck squamous cell carcinoma (HNSCC).
Data will include clinical response durability as well as HNSCC patient subgroup analysis. These data will be presented as a poster at the 2026 ASCO annual meeting, to be held May 29 – June 2, 2026 in Chicago, IL.
The KOL event will be held at the Marriott Marquis Chicago starting at 6:30AM CT on Monday, June 1st. The event will feature insights from leading HNSCC experts:
- Ari Rosenberg, MD – University of Chicago Medicine
- Glenn Hanna, MD - Dana-Farber Cancer Institute
- Cesar Augusto Perez Batista, MD - Sarah Cannon Research Institute
A live question and answer session will follow the formal presentation and discussion. To register for either virtual or in-person attendance, click here.
The ongoing three-part Phase 1/2 study has evaluated the safety, pharmacokinetics and efficacy of CRB-701 in 317 participants with advanced solid tumors associated with high Nectin-4 expression. CRB-701 is a next-generation antibody-drug-conjugate (ADC) targeting Nectin-4, that contains a site-specific, cleavable linker and a homogenous drug antibody ratio of 2, using MMAE as the payload.
Corbus recently announced broad alignment with the FDA on the registration path for CRB-701 in HNSCC.
About Ari Rosenberg, MD
Ari Rosenberg, MD, is a medical oncologist and Associate Professor of Medicine at the University of Chicago who specializes in using basic, translation and clinical research to improve the lives of his patients. As a clinical investigator, Dr. Rosenberg focuses on developing novel therapeutic strategies, including immunotherapy, for patients with head and neck cancer and thyroid cancer. He is also establishing methods to reduce treatment-related toxicity for better outcomes and quality of life. In 2025, Dr. Rosenberg was named to the prestigious list of 40 Under 40 in Cancer, an award that recognizes him as one of the nation's most promising young oncology professionals and celebrates his contributions to improve the lives of those affected by cancer.
About Glenn Hanna, MD
Glenn Hanna, MD, completed his fellowship training in hematology and medical oncology at Dana-Farber Cancer Institute in 2016. Prior to this, he earned his medical degree from Georgetown University School of Medicine in 2010, where he graduated summa cum laude, a member of Alpha Omega Alpha Honor Society and the Kober Medalist for academic excellence. He joined the faculty of the Center for Head and Neck Oncology in 2017. Dr. Hanna is the Director of the Center for Cancer Therapeutic Innovation (CCTI), the early drug development program at DFCI. His clinical and translational research efforts focus on precision medicine approaches to treat head and neck cancers. He has special interests in salivary gland cancers and rare head and neck malignancies, and in molecular and immunologic biomarker discovery.
About Cesar Augusto Perez Batista, MD
Cesar Augusto Perez Batista, MD, is Director of the Drug Development Unit at Sarah Cannon Research Institute at Florida Cancer Specialists in Lake Nona, Florida. A recognized cancer expert, he leads early-phase trials for solid tumors with a focus on head and neck cancer and serves as Executive Chair of the Head and Neck Cancer Research Group for the Sarah Cannon Network. He has served on several ASCO head and neck committees and is an ASCO Ambassador. Dr. Perez is an Affiliate Associate Professor at the University of Central Florida and previously co-led Phase 1 and head and neck oncology research at the University of Miami, following earlier faculty work at the University of Louisville, where he twice earned the Best Faculty Teacher Award. He trained at the Cleveland Clinic and the University of Miami, where he was Chief Fellow and received the Peter A. Cassileth, MD Award. He is board certified in medical oncology, hematology, and internal medicine.
About CRB-701
CRB-701 (SYS6002) is a next-generation antibody drug conjugate (ADC) targeting Nectin-4, that contains a site-specific, cleavable linker and a homogenous drug antibody ratio of 2, using MMAE as the payload. Nectin-4 is a clinically validated, tumor-associated antigen in urothelial cancer. The FDA has granted two Fast Track designations to CRB-701 in HNSCC and cervical cancer. CRB-701 is licensed from CSPC Megalith Biopharmaceutical Co. Ltd. China.
About Corbus
Corbus Pharmaceuticals Holdings, Inc. is a clinical-stage company focusing on promising new therapies in oncology and obesity and is committed to helping people defeat serious illness by bringing innovative scientific approaches to well-understood biological pathways. Corbus' pipeline includes CRB-701, a next-generation antibody drug conjugate for the treatment of Nectin-4-expressing tumors, and CRB-913, an orally delivered highly peripherally restricted CB1 inverse agonist for the treatment of obesity. Corbus is headquartered in Norwood, Massachusetts. For more information on Corbus, visit corbuspharma.com. Connect with us on X, LinkedIn and Facebook.
Forward-Looking Statements
This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to the Company's trial results, product development, clinical and regulatory timelines, including timing for completion of trials and presentation of data, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statement that are predictive in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management's current beliefs and assumptions.
These statements may be identified by the use of forward-looking expressions, including, but not limited to, "expect," "anticipate," "intend," "plan," "believe," "estimate," "potential," "predict," "project," "should," "would" and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors on our operations, clinical development plans and timelines, which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include those set forth in the Company's filings with the Securities and Exchange Commission. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.
INVESTOR CONTACTS:
Sean Moran
Chief Financial Officer
Corbus Pharmaceuticals
smoran@corbuspharma.com
Dan Ferry
Managing Director
LifeSci Advisors, LLC
daniel@lifesciadvisors.com
MEDIA CONTACT:
Liz Melone
Founder & Principal
Melone Communications, LLC
liz@melonecomm.com
